Speakers


  • speaker

    Iontcho Vlahov VP, Chemistry Endocyte Dr. Vlahov’s main scientific interest is the design and synthesis of complex biologically active molecules. In the past 15 years, as the head of Endocyte’s Discovery Chemistry department, Dr.Vlahov has been active in the discovery of personalized targeted approaches for the treatment of cancer and inflammatory diseases. His research efforts are aimed toward finding novel small molecule drug conjugates, linker systems, spacer units, and highly potent warheads. Read more...

  • speaker

    Pam Trail VP Regeneron Pharmaceuticals Pamela Trail is Vice President Oncology at Regeneron. Prior to this she served as the VP of Oncology at MedImmune and held positions at Seattle Genetics, Bayer, and Bristol-Myers Squibb. Dr. Trail has over 20 years of experience in developing antibody drug conjugates as cancer therapeutics. She received her PhD from the University of Connecticut.

  • speaker

    Mike Bienkowski Director SAFC

  • speaker

    Wendy Saffell- Clemmer Director, Research BPS Baxter Wendy Saffell-Clemmer, Director Research, Baxter, leads the BioPharma Solutions (BPS) R&D team, also known as Baxter’s Center of Excellence for Lyophilization. The BPS R&D team provides analytical development, formulation development, process development, lyophilization cycle development services to pharmaceutical company partners working with our Bloomington, IN, and Halle, Germany manufacturing facilities. Read more...

  • speaker

    Jan Anderl Director Heidelberg Pharma Jan Anderl is Director of the Biochemistry and Cell Biology Department at Heidelberg Pharma GmbH, a biopharmaceutical company located near Heidelberg; Germany. After receiving his Diploma in Biology from the Technical Universities in Darmstadt and Munich he was a postgraduate at the Bioorganic Chemistry group of the Max-Planck Institute for Medical Research, Heidelberg. Jan Anderl has research interests in bioconjugation chemistry, targeted drug delivery and protein chemistry. Dr. Anderl´s group is active in the evaluation of amatoxin-based ADCs, optimization of linker chemistry and protein engineering.

  • speaker

    Scott Miller Head, Special Projects Carbogen Amics Scott earned his Ph.D. in Chemistry at UC Irvine and conducted post-doctoral research with Prof. Dieter Seebach at the ETH Zürich. With over 20 years industry experience in the pharmaceutical and contract manufacturing industry, he has expertise in preclinical R&D through cGMP validation of API processes and has contributed to multiple IND, ANDA, and NDA filings. His projects have included collaboration with interdisciplinary project teams in Canada, Europe, Israel, and the USA. Scott joined CARBOGEN AMCIS AG in February 2012. He is currently responsible for the Antibody Drug Conjugate business expansion in Switzerland

  • speaker

    Robert Hollingsworth Senior Director MedImmune Dr. Robert Hollingsworth is Senior Director of Oncology Research at MedImmune, the biologics division of AstraZeneca. He oversees activities ranging from target identification to in vivo lead development, an leads MedImmune’s research on antibody-drug conjugates and other armed antibody approaches. Prior to joining MedImmune, Dr. Hollingsworth served as a Director at GlaxoSmithKline, leading teams in oncology and genomics research. He received a Ph.D. from the University of Colorado, and did post-doctoral studies at the University of Texas on the retinoblastoma tumor suppressor protein.

  • speaker

    Aad van de Leur Chief Operating Officer, Biopharmaceutical Development, Synthon Biopharmaceuticals B.V. Aad van de Leur is working at Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands, since January 2009. In his present function of COO he is responsible for all Biopharmaceutical operations activities including cell line development and process development for Cell Culture and Downstream Processing as well as DP and related analytical developments for biopharmaceutical products including monoclonal Antibodies and ADCs and the manufacturing of related IMPs. Read more...

  • speaker

    Chris O'Donnell Senior Director Pfizer Chris obtained a B.S. in Chemistry from the University of Illinois in Urbana/Champaign and a Ph.D. in Organic Chemistry in from the University of Wisconsin, Madison. After postdoctoral research at the University of California-Irvine, Chris joined Pfizer in 1999 as a medicinal chemist in the Neuroscience Medicinal Chemistry group. Chris has worked in the areas of addiction, cognition, psychosis, Alzheimer ’s disease, and bipolar. Read more...

  • speaker

    Nathan Tumey Principal Scientist Pfizer Nathan received his PhD in organic chemistry from Duke University in 2001. He worked on various small molecule medicinal chemistry programs for about 8 years before entering the ADC field in 2010. He is currently a senior principal scientist at Pfizer where he works on optimizing and developing new conjugation chemistries for various ADC projects. His particular areas of interest include ADC stability, site-specific conjugation technology, and ADC characterization.

  • speaker

    Sarah Hoofing Associate Scientist Amgen Sarah Hoofring is currently an Associate Scientist in the Clinical Immunology Department at Amgen, Thousand Oaks, CA. She obtained her Bachelor of Science in Biochemistry and Molecular Biology from the University of California, Irvine prior to joining Amgen in 2006. Her current responsibilities at Amgen include the development of immunogenicity methods capable of detecting binding antibodies to therapeutics in support of both early and late stage clinical studies (Pre-clinical, Phase I, Phase II, and Phase III). Read more...

  • speaker

    Silvano Sanchini Researcher MIT I am a medicinal chemist with a thorough experience in the design, synthesis, purification and characterization of compounds to support both “lead generation” and “lead optimization” projects, but I have also been working on the total synthesis of complex natural products and with bio-conjugates. During my postdoc in the Novartis ADC group (2011-2014) I have been focusing on the development of innovative imaging agents endowed with a double selectivity mechanism for delivery to tumor tissues.

  • speaker

    Clark Pan Senior Director Sanofi Dr. Clark Pan has over 20 years of protein engineering experience, including the past 8 years at Sanofi/Genzyme. He currently holds the position of senior director of Protein Engineering at the Framingham, MA site of Sanofi Biologics. Prior to Genzyme, he spent 8 years at Bayer, where he invented the long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027, which recently completed a successful phase 3 trial. Dr. Pan received his PhD from University of California, Los Angeles and completed a post-doctoral fellowship at Genentech.

  • speaker

    Ho Cho Executive Director, Biotherapeutics Celgene Dr. Ho Sung Cho is Executive Director, Biotherapeutics at Celgene. Dr. Cho is a Protein Medicinal Chemist with over 24 years of experience in recombinant protein expression, purification, modification, and analysis. Prior to joining industry, Dr. Cho worked on the structural genomics project at the Lawrence Berkeley National Labs. He received his Ph. D. in Chemistry from the University of California at Berkeley.

  • speaker

    Bill Zamboni Professor UNC School of Pharmacy William Zamboni is an associate professor in the UNC Eshelman School of Pharmacy and UNC Lineberger Comprehensive Cancer Center. Zamboni’s research program is part of the Division of Pharmacotherapy and Experimental Therapeutics in the UNC Eshelman School of Pharmacy and Molecular Therapeutics in the UNC Lineberger Comprehensive Cancer Center. Read more...

  • speaker

    John Lambert EVP & CSO ImmunoGen John Lambert joined ImmunoGen in 1987. Prior to this, he was an Assistant Professor at Harvard Medical School. Dr. Lambert holds a Ph.D. in Biochemistry from the University of Cambridge.

  • speaker

    Niclas Tan Senior Scientist Takeda Dr. Niclas Tan has 5 years of experience at Takeda Pharmaceuticals International Co. in the development and characterization of recombinant monoclonal antibodies and antibody drug conjugates in various therapeutic areas from early- and late-stage development through commercialization. He is currently a CMC liaison in the Analytical Development group for an ADC program in clinical trials. In this role, his responsibilities include defining the analytical comparability and product characterization strategy for drug candidates. Read more...

  • speaker

    Laurent Ducry Group Leader, Bioconjugates R&D Lonza

  • speaker

    Fred Jacobson Staff Scientist Genentech

  • speaker

    Nazzareno Dimasi Senior Scientist MedImmune Nazzareno Dimasi received his Ph.D. in Molecular and Cellular Biology from the University of Rome Tor Vergata (Rome, Italy). He then pursued postdoctoral work at the Center for Advanced Research in Biotechnology of the University of Maryland (Rockville, Maryland) where he worked on 3D-structural determination using X-Ray crystallography of proteins of the innate immune system. Subsequently, he joined the Gaslini Children Hospital (Genova, Italy) where he worked on structure-function relationship of NK and T-cell receptors. In 2007, he joined MedImmune (Gaithersburg, Maryland) where he began research on multispecific antibodies, antibody-drug conjugates and novel conjugation modalities for oncology applications.

  • speaker

    Marco Timmers CSO Synthon Dr. Marco Timmers received his PhD in Bio-Organic Chemistry from Leiden University, The Netherlands. In 1997, he joined Organon, where he became involved in various R&D projects in immunology, endocrinology and cardiovasculars. In 2001, he was appointed Head of Medicinal Chemistry, responsible for endocrinology and endocrinological oncology and combined this role with several project-management positions up to clinical PoC. Read more...

  • speaker

    Paul Davis Owner Quanta Biodesign Paul Davis’ vision for providing a full range of specifically designed single molecule reagents for therapeutic and diagnostic applications can be seen in the expanding range of products offered by Quanta. Paul has his Ph.D. in chemistry, and has almost 30 years of R&D experience. Before starting Quanta, he held key technical/management positions at Molecular Probes Life Technologies and Pierce Thermo Fisher.

  • speaker

    David Rabuka President, Chief Scientific Officer and Founder Redwood Bioscience Dr. Rabuka received a Ph.D. in Chemistry at the University of California, Berkeley as a Chevron Fellow in the lab of Professor Carolyn Bertozzi. His research included developing and applying Redwood’s platform technology to cell surface modification. Read more...

  • speaker

    Jagath Junutula VP, Antibody Discovery & Development Cellerant Therapeutics Jagath Reddy Junutula, PhD joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. Read more...

  • speaker

    David Meininger Merck Dr. Meininger joined Merck in 2011 as Head of Protein Sciences. He served as a member of the Biologics Review & Licensing Committee, as champion of the Adimab collaboration, as co-champion of the Ambrx antibody-drug conjugate collaboration and played a strategic role on other Merck partnerships. In 2013, Dr. Meininger joined the new Merck Research Labs Business Development & Licensing organization. His BD&L responsibilities include evaluation and transaction of in- and out-licensing deals involving biologic assets from pre-clinical through phase II, support of the Merck Research Ventures Fund team and other BD activities.

  • speaker

    Tom Pillow Scientist Genetech Thomas Pillow received his Ph.D from Stanford University in organic chemistry under the direction of Professor Paul Wender on the design, synthesis, and evaluation of novel drug delivery methodologies. Upon graduation he moved to Genentech where he is currently a scientist in the discovery chemistry department leading Genentech’s chemistry effort on antibody-drug conjugates.

  • speaker

    Yuki Abe Senior Director Daiichi Sankyo

  • speaker

    Sanela Bilic Director, Oncology Clinical Phamacology Novartis Dr. Sanela Bilic has spent over 10 years in industry working on large proteins. She has been with Novartis since 2004. Sanela is Director, Principal Fellow, Oncology Clinical Pharmacology and oversees the Clinical Pharmacology strategy of Antibody Drug Conjugates and biologics at Novartis. Dr. Bilic is integral part of large molecule programs from early discovery to late stage development and provides strategic support for those. Prior to Novartis, Dr. Bilic completed a postdoctoral fellowship in Drug Development with focus on Clinical Pharmacology in Infectious diseases and Oncology at SUNY at Buffalo. Dr. Bilic has over 40 national and international posters, invited talks, and publications. Dr. Bilic obtained her MBA and PharmD degrees from Drake University.

  • speaker

    Tim Lowinger CSO Mersana Therapeutics Tim Lowinger joined Mersana in 2008. He has over eighteen years of experience in the pharmaceutical/biotech industry and brings a wealth of international experience to his role in leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he contributed to the discovery of more than 15 pre-clinical and clinical candidates in a variety of indications. Read more...

  • speaker

    Ed Reilly Associate Director II, Cancer Therapeutic Abs, GPRD, Cancer Discovery AbbVie Ed Reilly is an immunologist who trained as a Postdoctoral Fellow and Visiting Scientist at the MIT Center for Cancer Research in the laboratory of Herman Eisen. He presently serves as a Project Director in the Oncology Discovery Group within AbbVie where he leads several late stage Discovery ADC programs.

  • speaker

    Jim O'Leary CMO ImmunoGen Prior to joining ImmunoGen as Chief Medical Officer, Dr. O'Leary held positions of increasing responsibility at Bayer Corporation (2006-2008) and Pfizer Inc. (2000-2006) Prior to joining Pfizer, Dr. O'Leary held the position of Medical Reviewer, Division of Oncology Drug Products, at the US Food and Drug Administration (1998-2000). He completed a fellowship in Hematology/Oncology at New York University Medical Center in 1998.

  • speaker

    Bob Herbst Scientist ImmunoGen Robert received his PhD in bioinorganic chemistry from University of Massachusetts, Amherst where he worked on the interface of chemistry and biology. Robert joined ImmunoGen in 2010 as a process development scientist. His areas of focus include developing, optimizing, and transferring conjugation processes for several ADC programs. His current areas of interest are process robustness and scalability from the development lab to manufacturing.

  • speaker

    Dave Bramhill Consultant Bramhill Biological Consulting

  • speaker

    James Patterson Post doc Scripps Dr. James Patterson is a postdoctoral research associate in the laboratory of Dr. Carlos F. Barbas, III at The Scripps Research Institute (TSRI). James works on new bioconjugation chemistries for the site-specific modification of proteins and antibodies. Prior to joining TSRI, he earned his Ph.D. in Chemistry (Chemical Biology) at Indiana University in the laboratory of Dr. Read more...

  • speaker

    Alan Rigby VP Eli Lilly

  • speaker

    Arijit Chakravarty Director DMPK Takeda

  • speaker

    Christian Manzke Director, Marketing & Sales, Integrated Solutions Sartorius Stedim Christian is responsible for a team of process specialists who are working on customer specific projects in the biopharmaceutical industry. To understand the position of the customer and the needs of the process does allow him and his team to develop taylor made technical and commercial solutions. More than 20 years of experience in the areas of fermentation, cell culture and down stream processing are the foundation of the knowledge to be shared. Read more...

  • speaker

    Aditya Wakankar Associate Director Stemcentrx Bio: Dr. Aditya Wakankar is currently the Associate Director of Formulation and Analytical Development at Stem CentRx Inc. Prior to joining Stem CentRx, Aditya was a Scientist and CMC Team Leader at Genentech for 6+ years and was responsible for developing the commercial formulation for Kadcyla® (T-DM1). Also serving as an Assay Sub-Team leader for the T-DM1 program, his team was responsible for developing the analytical control system for the Kadcyla® BLA filing. Aditya has obtained his M.S. and Ph.D. from The University of Kansas in the department of Pharmaceutical Chemistry

  • speaker

    William Galush CMC Team Lead Genentech

  • speaker

    Daryl Drummond Senior Director Merrimack

  • speaker

    Leonard Reyno CMO Agensys Leonard Reyno is Senior Vice President & CMO of Agensys. Prior to this, he served as the Senior Director at Cytokines, and a Medical Director at Genentech. He is also a Physician

  • speaker

    David Goldenberg Chairman & CSO Immunomedics David Goldenberg, ScD, MD, is the founder of Immunomedics, Inc., where he is Chairman and Chief Scientific Officer. He is also founder and President of the Center for Molecular Medicine and Immunology (and its Garden State Cancer Center subsidiary), all in Morris Plains, NJ. Dr. Goldenberg pioneered and coined the terms radioimmunodetection and radioimmunotherapy, developing two of the first antibody-based commercial imaging agents, CEA-Scan(R) and Leukoscan(R). Read more...

  • speaker

    Greg Landes Biotechnology Consultant DNA Bridges Gregory Landes has over 30 years of experience in the biotechnology industry with broad expertise in target discovery and validation, antibody and ADC drug discovery and preclinical development, molecular biology, genetics, genomics, and biochemistry. He currently consults with over a dozen companies in the disciplines described above as well as automation, biosimilars and antibody effector function. In addition, he leads workshops at national antibody conferences in a variety of areas of expertise including antibody effector function and antibody drug conjugates. Read more...

  • speaker

    Maria Elena Guadagno Business Director BSP Pharmaceuticals

  • speaker

    Firelli Alonso-Caplen Senior Director Pfizer Dr. Firelli Alonso-Caplen is a Senior Director at Pfizer, Inc. She heads the Biotherapeutics and Vaccines Outsourcing group in Worldwide Research and Development. Fi has more than 30 years of combined experience in research, development, and cGMP production of biological products and vaccines, and more than 10 years experience in outsourcing, project / contract management, and technology transfer to qualified third parties. Her areas of expertise include viral vectors and vaccine development, biotherapeutics and vaccine process development and cGMP production, project management, technology transfer, and outsourcing

  • speaker

    Morris Rosenberg Consultant Mrosenberg Consulting Dr. Rosenberg is widely regarded as an expert in the development, scale up and manufacturing of recombinant human therapeutics. He has over 28 years industry experience and was most recently employed as Executive Vice President of Development and Manufacturing at Seattle Genetics where he played a key role in the development of their antibody drug conjugate platform and the successful launch of Adcetris for Hodgkin Lymphoma. Read more...

  • speaker

    Sarah Pogue Director, Target Validation Teva Sarah Pogue, Ph.D. is the Director of Biologics Validation in the newly formed Biologics Division of Teva Pharmaceuticals. Prior to joining Teva, Sarah served in scientific management positions at Coulter Pharmaceuticals, Corixa, Medarex, Arana Therapeutics and Cephalon, Inc. Sarah received a Bachelors of Science degree from the University of California, Davis and a PhD degree from Stanford University where she studied B cell development with Dr. Chris Goodnow. Sarah did a post doctoral fellowship with Dr. Joe Bolen at the DNAX Research Institute studying AKT signaling.

  • speaker

    Andy Polson Senior Scientist, Cancer Targets Genentech

  • speaker

    George Badescu Director, Scientific Affairs Polytherics Dr Badescu has been leading PolyTherics’ ADC Program since its inception and is co-inventor on several PolyTherics patents in the field of bioconjugation and ADCs. Prior to this, George has worked on lead identification by viral display technologies, antibody engineering and characterisation of antibody-hapten interactions. George received his PhD from the University of Warwick.

  • speaker

    Giulio Casi Head, ADCs Philogen Giulio Casi studied chemistry at Florence University graduating with a thesis on the synthesis and evaluation of potent apoptotic inhibitors, with special attention to synthetic methods developments. In 2007 he earned his doctorate in chemistry under the supervision of Prof. Dr. Donald Hilvert, at the institute of chemistry and applied biosciences of the ETH Zürich. Read more...

  • speaker

    Thomas Davis CMO Celldex Therapeutics Dr. Davis has been involved in clinical cancer immunotherapy in academia, government and industry for over a decade. He trained at Johns Hopkins, Georgetown and Stanford Universities. While at Stanford, Dr. Davis worked with Dr. Ronald Levy, and participated in all phases of clinical development of anti-CD20 antibodies, including rituximab and tositumomab, in both their unlabeled and radiolabeled versions. He also was involved in the translational development of tumor specific idiotype vaccines for the treatment of B-cell malignancies Read more...

  • speaker

    David Miao Founder & CSO Concortis Biosystems David Miao, Ph.D., is Chief Scientific Officer and Cofounder of Concortis Biosystems Corp. His responsibilities in this role encompass managing Concortis internal R&D and global collaborations, including strategic planning, project management, budgeting, and resource allocation. Read more...

  • speaker

    Mahendra Deonarain CSO Photbiotics

  • speaker

    Jonathan Drachman CMO Seattle Genetics Jonathan Drachman joined Seattle Genetics in November 2004. He oversees the company's research, preclinical and early clinical development activities. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School.

  • speaker

    John Gelber Director, Biopharma Development Waters As Director of Biopharmaceutical Business Development for Waters Corporation, John Gebler is responsible for Waters global biopharmaceutical LC/MS business development and strategy. John earned his Ph.D. at the University of Utah in the Department of Chemistry and did his post-doctoral study at the University of British Columbia Vancouver. Read more...

  • speaker

    Sandhya Girish Senior Scientist Genentech Dr. Girish is a Senior Scientist and a Group Leader in the department of clinical pharmacology at Genentech. Dr. Girish is the global clinical pharmacology lead for antibody drug conjugates (ADCs) in clinical development. Her group is currently focused on providing strategic clinical pharmacology and translational support and leadership for the ADC platform, including T-DM1 (Kadcyla), vc-MMAE-ADCs etc. Read more...

  • speaker

    Marjorie Green Medical Director - Product Development Oncology Genentech Marjorie C. Green, MD is a Medical Director working in Oncology Product Development for Genentech, Inc. She previously was an Associate Professor of Medicine in the Department of Breast Medical Oncology and the Medical Director of the Nellie B Connally Breast Center at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Green is an experienced clinical researcher, serving as PI for Phase I-III trials including several studies evaluating neoadjuvant therapy for breast cancer and has numerous publications in this field. Read more...

  • speaker

    Paul Parren SVP, Scientific Director Genmab

  • speaker

    Floris van Delft CSO SynAffix Floris van Delft (PhD) is a founder and the Chief Scientific Officer of SynAffix. Previously, Floris held a position as associate professor at the Radboud University Nijmegen, with special focus on click chemistry and protein conjugation technologies, before shifting his professional activities full-time from academic research to SynAffix in 2013. Read more...

  • speaker

    Maarten Postema Director, Chemistry Eisai

  • speaker

    Xiuxia Sun Scientist ImmunoGen Xiuxia Sun is a Scientist in the Biochemistry group at ImmunoGen, Inc. headquarted in Waltham, MA. Her work focuses on the preclinical development of antibody-drug conjugates (ADCs). Current efforts in her group include production, characterization, ADME, and mechanistic studies of ADCs. Read more...

  • speaker

    Mark Wright Site Lead, Grangemouth Piramal Healthcare Mark Wright is the Development Manger at Piramal Healthcare for Research and Development projects in the antibody drug conjugate field. He has been working with ADC projects at Piramal Healthcare for 6 years and has been working with protein - toxin conjugates for 9 years.

  • speaker

    Jon Terrett Senior Director, Oncology CytomX Therapeutics Jon is currently Senior Director of Oncology & Bioconjugate Chemistry at CytomX where he is responsible for the development of cancer-targeting Probodies and Probody drug conjugates. His previous positions were at Oxford Biotherapeutics and Medarex (now BMS ). For the last 10+ years Jon’s focus has been on the development of antibody drug conjugates directed against novel targets leading to a wealth of experience into the varied and complex components of ADCs.

  • speaker

    Nathan Ihle VP, CMC Strategy Seattle Genetics Nathan Ihle joined Seattle Genetics in March 2002 and was named Vice President, CMC Strategy and Management in March 2014. Previously he served as Executive Director of CMC Strategy and Management and Director, Process Chemistry. In his current position, Nathan has responsibility for Process Chemistry, CMC strategy and CMC project management for all drug development and commercial programs at Seattle Genetics Read more...

  • speaker

    Neil Josephson Medical Director Seattle Genetics

  • speaker

    Ananda Seneviratne Principal Scientist Agensys

  • speaker

    Mark Flory Principal Scientist Igenica Mark Flory is a Principal Scientist at Igenica Biotherapeutics, a biopharmaceutical company focused on the creation of breakthrough antibody-based therapeutics to address the unmet medical needs of cancer patients. Read more...

  • speaker

    Juan Manuel Domínguez Project Manager, R&D Department PharmaMar